We offer peptide, hormone, exosome, and NAD therapy
In laboratory studies, inhibiting NNMT has been investigated for effects on cellular NAD+ levels and adipocyte (fat-cell) metabolism
Metabolic Syndrome Management (with professional guidance): For individuals looking for support in managing aspects of metabolic syndrome related to fat accumulation, AOD9604 presents a specific research-backed approach, always under the supervision of a healthcare provider
This level of detail is what separates preliminary research from publication-quality work
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
